Tredence Acquires KMK Consulting to Expand Healthcare and Life Sciences Business

Tredence has acquired life sciences analytics and consulting firm KMK Consulting as the AI and data science company looks to expand its presence in the healthcare and life sciences sector.

The acquisition, announced on June 22, brings together Tredence's AI and data science capabilities with KMK's pharmaceutical industry expertise. Financial terms of the deal were not disclosed.

Headquartered in Morris Plains, New Jersey, KMK Consulting works with eight of the world's top 10 pharmaceutical companies and has more than two decades of experience across commercial analytics, market research, and Real World Evidence (RWE), according to the announcement from Tredence.

The deal forms part of Tredence's strategy to build healthcare and life sciences into a larger business segment. The company said it expects the sector to account for approximately 25% of its overall revenue by 2028.

Focus on Healthcare and Life Sciences

Tredence said the acquisition combines KMK's life sciences expertise with its agentic AI capabilities to help pharmaceutical companies accelerate AI adoption across research, development, supply chain, and commercial operations.

"This acquisition positions Tredence as a differentiated AI partner across the full Molecule-to-Market journey, combining KMK's Life Sciences domain depth with Tredence's applied AI, data engineering, and decision intelligence capabilities," the company said in its announcement.

Shub Bhowmick, Co-Founder and CEO, Tredence, said domain expertise remains central to the company's strategy.

"While Tredence has consistently operated at the leading edge of AI and Data Science, our true differentiator has always been deep domain expertise. The acquisition of KMK reinforces this philosophy, bringing unparalleled strength in Pharmaceuticals and Life sciences," Bhowmick said.

The acquisition also strengthens Tredence's position within the Veeva ecosystem, a key software platform used by pharmaceutical companies to manage commercial operations, medical engagement, and incentive compensation. The growing importance of Veeva's role in life sciences technology has been evident as the company expands its healthcare software portfolio through acquisitions and AI initiatives.

Industry Demand for Specialized AI Expertise

The transaction comes as pharmaceutical companies continue increasing investments in AI across research, clinical development, and commercial functions.

According to Tredence, the global market for AI in life sciences is expected to reach $69.3 billion by 2031. The company said combining KMK's industry expertise with its AI capabilities will help customers accelerate adoption in process-intensive and highly regulated environments.

Michael Karbachinskiy, Founder and CEO, KMK Consulting, said the deal will allow the firm to extend its capabilities through AI and data science technologies.

"At KMK, our foundation has always been deep, long-standing expertise in Life sciences—understanding not just the science, but how it translates into real-world decisions and outcomes. With Tredence's strength in AI and Data Science, we now have the opportunity to amplify that expertise and deliver even greater impact to our clients," Karbachinskiy said.

The acquisition follows a broader trend across healthcare and life sciences, where organizations are increasingly combining AI platforms with domain-specific expertise to support drug development, clinical operations, and commercial decision-making. Interest in deploying AI across regulated life sciences workflows has also continued to grow as companies seek to scale adoption beyond pilot projects.

Tredence employs more than 4,200 people globally and serves customers across retail, consumer packaged goods, healthcare, telecommunications, travel, and industrial sectors. The company said the acquisition advances its long-term healthcare and life sciences growth strategy.